A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache
NCT ID: NCT00287781
Last Updated: 2008-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2002-01-31
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
NCT07061847
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines
NCT00690716
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
NCT03488563
Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department
NCT03576820
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1
NCT06462781
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Breast feeding
* Allergic to Lidocaine
* Worst or first Headache
* Abnormal neurological exam
* Substance abuse within 6 months
* Cardiac, liver or pulmonary disease
* Participation n another study within 30 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kern Medical Center
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rick McPheeters, DO FAAEM
Role: PRINCIPAL_INVESTIGATOR
Kern Medical Center UCLA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kern Medical Center
Bakersfield, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#04028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.